ImmuPharma plc
IMM.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £118 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | £64 | £38 | £118 | £0 |
| Gross Profit | -£64 | -£38 | -£118 | £118 |
| % Margin | – | – | – | 100% |
| R&D Expenses | £1,162 | £2,022 | £2,023 | £3,650 |
| G&A Expenses | £1,031 | £1,020 | £847 | £1,011 |
| SG&A Expenses | £1,119 | £1,161 | £847 | £1,628 |
| Sales & Mktg Exp. | £88 | £140 | £0 | £616 |
| Other Operating Expenses | £394 | -£38 | £42 | £1,427 |
| Operating Expenses | £2,675 | £3,145 | £2,911 | £6,705 |
| Operating Income | -£2,280 | -£3,063 | -£3,029 | -£6,587 |
| % Margin | – | – | – | -5,565.7% |
| Other Income/Exp. Net | -£104 | -£356 | -£1,427 | -£2,354 |
| Pre-Tax Income | -£2,779 | -£3,419 | -£4,456 | -£8,941 |
| Tax Expense | -£296 | -£497 | -£649 | -£767 |
| Net Income | -£2,483 | -£2,922 | -£3,807 | -£8,174 |
| % Margin | – | – | – | -6,906.6% |
| EPS | -0.006 | -0.008 | -0.013 | -0.033 |
| % Growth | 25.9% | 35.7% | 61.2% | – |
| EPS Diluted | -0.006 | -0.008 | -0.013 | -0.033 |
| Weighted Avg Shares Out | 413,917 | 360,715 | 302,913 | 251,164 |
| Weighted Avg Shares Out Dil | 416,437 | 362,005 | 302,913 | 251,164 |
| Supplemental Information | – | – | – | – |
| Interest Income | £6 | £3 | £1 | £1 |
| Interest Expense | £2 | £2 | £2 | £124 |
| Depreciation & Amortization | £64 | £38 | £118 | £114 |
| EBITDA | -£2,611 | -£3,025 | -£2,911 | -£8,703 |
| % Margin | – | – | – | -7,353.6% |